SanFran! Nice to hear from you.

After further thought, I'm not convinced much has changed between the AGM & BIO-Europe statements and the MD&A statements. At AGM & BIO-Europe, they expected last dosing by end 2018. MD&A stated trial completion expected H1 2019. MD&A didn't state any change to expected end of dosing.....only trial completion. Keep in mind that trial completion could encompass both the end of dosing and the 4-6 week safety follow up period that occurs after dosing ends. H1 2019 could still mean Jan 2019 or Feb 2019.....it doesn't have to be interpreted as late H1 2019. With a 2-3 month adjudication period, we could still see top-line late Q1 2019 or early Q2 2019 with full results at a May or June 2019 conference. This is all pretty much consistent with the AGM & BIO-Europe timelines. We should know more when we see/hear the company presentation at Biotech Showcase in less than 4 weeks.

DM explained the logic about the 270 events at the AGM three months ago. Those additional ~20 events byeond the 250 that occur during dosing are expected to occur after dosing has completed during the safety follow up and adjudication period.

BearDownAZ